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Abstract
Golden retriever muscular dystrophy (GRMD) is a genetic myopathy corresponding to Duchenne muscular dystrophy (DMD)
in humans. Muscle atrophy is known to be associated with degradation of the dystrophin-glycoprotein complex (DGC) via
the ubiquitin-proteasome pathway. In the present study, we investigated the effect of bortezomib treatment on the muscle
fibers of GRMD dogs. Five GRMD dogs were examined; two were treated (TD- Treated dogs) with the proteasome inhibitor
bortezomib, and three were control dogs (CD). Dogs were treated with bortezomib using the same treatment regimen used
for multiple myeloma. Pharmacodynamics were evaluated by measuring the inhibition of 20S proteasome activity in whole
blood after treatment and comparing it to that in CD. We performed immunohistochemical studies on muscle biopsy
specimens to evaluate the rescue of dystrophin and dystrophin-associated proteins in the muscles of GRMD dogs treated
with bortezomib. Skeletal tissue from TD had lower levels of connective tissue deposition and inflammatory cell infiltration
than CD as determined by histology, collagen morphometry and ultrastructural analysis. The CD showed higher expression
of phospho-NFkB and TGF-b1, suggesting a more pronounced activation of anti-apoptotic factors and inflammatory
molecules and greater connective tissue deposition, respectively. Immunohistochemical analysis demonstrated that
dystrophin was not present in the sarcoplasmic membrane of either group. However, bortezomib-TD showed higher
expression of a- and b-dystroglycan, indicating an improved disease histopathology phenotype. Significant inhibition of 20S
proteasome activity was observed 1 hour after bortezomib administration in the last cycle when the dose was higher.
Proteasome inhibitors may thus improve the appearance of GRMD muscle fibers, lessen connective tissue deposition and
reduce the infiltration of inflammatory cells. In addition, proteasome inhibitors may rescue some dystrophin-associated
proteins in the muscle fiber membrane.
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Introduction
Golden retriever muscular dystrophy (GRMD) is a degenerative
myopathy corresponding to Duchenne muscular dystrophy
(DMD) in humans. Both GRMD and DMD are caused by the
absence of a functional dystrophin protein. In GRMD, this
absence is the result of a frame-shifting point mutation in the
dystrophin gene, whereas deletions are the most frequent
mutations in DMD patients [1],[2].
Similarly to DMD patients, GRMD dogs suffer from repeated
cycles of muscle necrosis and regeneration, muscle wasting and
fibrosis, postural abnormalities, respiratory or heart failure and
premature death [3],[4],[5],[6]. As GRMD dogs closely resemble
DMD patients, both in terms of body weight and in the
pathological expression of the disease [7], they are excellent
animal models for the study of pathogenic mechanisms and
therapeutic interventions.
Dystrophin is located beneath the sarcolemma and is part of a
large dystrophin-dystroglycan complex termed the dystrophin-
glycoprotein complex (DGC); it includes the dystroglycan complex
(a and b) and the sarcoglycan complex (a, b, c and d) [8]. The
DGC is a critical link in the transmission of force between the
contractile machinery of muscle fibers and the extracellular
matrix. When dystrophin is defective or absent, the myofiber is
fragile and the sarcolemma is readily damaged in response to
exercise, leading to myofiber necrosis [1], [4]. The loss of
dystrophin leads to the absence of or a great reduction in the
components of the DGC, as has been described for skeletal muscle
fibers from DMD patients and mdx mice [9], [10].
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The current treatment for DMD is the administration of
corticosteroids; these broad-based anti-inflammatory drugs de-
crease inflammatory cell populations in dystrophic muscle and
increase myofiber mass, although their precise mechanism of
action in DMD is not yet known and is under intense investigation
[11],[12]. Steroids are associated with severe adverse side effects
such as weight gain and osteoporosis, and the response to steroid
therapy is variable among individual patients [13], [14].
Bortezomib (VelcadeH) is a dipeptide boronic acid proteasome
inhibitor that works by reversible inhibition of the chymotrypsin-
like activity of the proteasome [15], [16]. Previous reports have
shown that proteasome inhibitors are able to block the activation
of nuclear factor-kB (NFkB). This factor is involved in inflamma-
tory and acute stress responses. Studies have reported that the
NFkB pathway is activated in DMD and that it is involved in
muscle degeneration and regeneration in dystrophin-deficient
fibers [17], [18]. Treatment with bortezomib and another
proteasome inhibitor, MLN-273, caused a significant decrease in
the expression of the activated form of NFkB in the skeletal muscle
of mdx mice [19].
Other mechanisms involved in DMD are related to transform-
ing growth factor-beta 1 (TGF-b1), which is the best-characterized
fibrogenic mediator [20]. The activation of NFkB and the acute
activation of TGF-b1 in human dystrophin-deficient muscle tissue
cause the failure of metabolic pathways later in the disease and
appear to be associated with symptoms and muscle wasting in
DMD [21]. TGF-b1 is overexpressed in human dystrophic
muscle, in degenerative muscle disease [22],[23] and in the
skeletal muscle of dogs with GRMD [24]. Increased TGF-b1
mRNA levels are also associated with the initial stage of tissue
fibrosis [22]. These findings suggest that TGF-b1 is involved in the
fibrotic process of human muscle dystrophy.
Several lines of evidence have suggested that enhanced
activation of the proteasome pathway underlies the pathogenesis
of various diseases including skeletal muscle atrophy and muscle
dystrophy [25],[26],[27],[28],[29]. This has led to the suggestion
that proteasome inhibitors such as bortezomib might rescue the
structure of dystrophin and improve muscle condition.
Recent in vitro studies on Duchenne and Becker muscular
dystrophy and in vivo studies in mdx mice have demonstrated that
inhibitors of the proteasome pathway can effectively block the
degradation of dystrophin and dystrophin-associated proteins and
improve the morphology of dystrophin-deficient skeletal muscle
[19], [27], [30].
It should be noted that the use of GRMD dogs for collecting
data related to the reconstruction of muscle function is not trivial
[7]. Raising just 2 GRMD dogs and treating them with drugs such
as bortezomib for one month costs approximately US$ 15,000.00.
We therefore agree with the recent article [31] about the
limitations of using GRMD dogs during preclinical trials.
The present study analyzed the effect of bortezomib treatment
on the muscle fibers of GRMD dogs. Dogs were treated with
bortezomib using the same treatment regimen used for multiple
myeloma and were assessed for activation of the ubiquitin-
proteasome proteolytic pathway during the rapid loss of muscle
protein in dystrophin-deficient skeletal muscle. Pharmacodynam-
ics were evaluated by measuring the inhibition of 20S proteasome
activity in whole blood following treatment and comparing it to
that of untreated dogs (CD). We performed immunohistochemical
analysis of muscle biopsy specimens to evaluate the rescue of
dystrophin and dystrophin-associated proteins in the muscles of
GRMD dogs treated with bortezomib.
Methods and Ethics Statement
Five GRMD dogs were selected from the GRMD-Brazil kennel
at the Department of Surgery of the University of Sa˜o Paulo. This
research was approved by the Bioethics Committee of the School
of Veterinary Medicine and Animal Science, protocol number
893/2006.
Animal Models
Five GRMD dogs (four months old at the beginning of the
study) and three healthy dogs were used to analyze and compare
the architecture of muscle fibers. Four of the dogs came from the
same litter and one came from another litter, but all were born
during the same week. We chose dogs of the same age to reduce
phenotypic variability, which is characteristic of the canine model
of muscular dystrophy. We followed our previous approach using
morphological tools to characterize different phenotypes in
GRMD dogs [32].
The dogs were kept under humane conditions that included
proper meals, hygiene and monitoring by veterinarians. The
diagnosis of muscular dystrophy was confirmed in GRMD dogs by
DNA testing at one week of age.
The GRMD dogs were separated into two groups: two treated
dogs (TD) and three control dogs (CD). Beginning the study with
four-month-old dogs was important because they remained
ambulant and because clinical signs of the disease were not
severe, as the fibrotic process had not yet fully developed at this
age [33].
Skeletal muscle tissue was collected from TD and CD for
further analysis before treatment (time zero, T0) and after
treatment (time one, T1) 9 weeks later. A portion of the samples
collected in the biopsy was frozen at 280uC until western blot
analysis.
Administration of Bortezomib
A 3.5-mg vial of bortezomib (VelcadeH) was reconstituted with
3.5 mL normal saline (USP), such that the reconstituted solution
contained 1 mg/mL. Administration of bortezomib was per-
formed with a 3 to 5 second intravenous injection twice weekly
(Mondays and Thursdays) for 2 weeks (days 1, 4, 8, and 11),
followed by a 10 day rest period (days 12–21). This protocol
constituted 1 cycle of treatment in accordance with the therapy
stipulated by the manufacturer. A total of 3 cycles of treatment
were administered.
The doses in this study were in accord with those administered
to human myeloma patients [34]. The first cycle was 1.3 mg/m2,
the second was 1.45 mg/m2 and the third cycle was 1.65 mg/m2.
We changed the dose between cycles because the effect of the
proteasome inhibitor is dose-dependent and because better results
have been observed at higher concentrations [19,27]. The dosage
was partially influenced by pharmacodynamic data that predict a
gradual approach up to 90% inhibition as the target for the
maximal level of safe inhibition [35].
Histological and Morphometric analyses
Muscle samples were fixed in a 4% paraformaldehyde solution.
Muscle sections of 5 mm thickness were stained with hematoxylin
and eosin to evaluate morphology and disease progression.
Transverse sections were stained with picrosirius red to distinguish
skeletal muscle from collagen fibers. To accurately quantify
collagen-positive areas, thirty randomly selected low-power fields
per muscle section slide from each dog at each time point (T0 and
T1) were microscopically analyzed (Axioplan 2; Carl Zeiss, Inc.).
Digital pictures were captured with a video archival system using a
Bortezomib Therapy in Canine Dystrophy
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digital television camera system (AxioCam High Resolution Color,
Carl Zeiss, Inc.). An automated software analysis program
(KS400, Carl Zeiss, Inc.) was used to determine the percentage
of stained areas in the digital photomicrographs [36].
Immunohistochemical analysis
The paraffinized 5 mm sections of skeletal muscle were placed in
an incubator at 55uC for 1 hour, deparaffinized and dehydrated,
boiled in citrate buffer and incubated with 3% hydrogen peroxide
in phosphate-buffered saline (PBS, Biochrom KG, Germany) to
inhibit endogenous peroxidases. The sections were then washed
two times in PBS and pre-treated with 10% normal goat serum
diluted in PBS to block non-specific binding. The antibodies were
diluted in 10% normal goat serum. Incubations were conducted
overnight at 4uC. After three washes in PBS, sections were
incubated with a biotinylated secondary goat anti-mouse IgG
antibody or a goat anti-rabbit IgG antibody (VectorH) diluted
1:500 in PBS. For all antibodies, immunoreactivity was detected
by a streptavidin-biotin-peroxidase (DakoH) technique using 3,39-
diaminobenzidine (DakoH). Sections were then stained for 30 s
with hematoxylin, dehydrated, and mounted.
Phospho-NFkB-positive nuclei were counted in 10 random
fields at 406magnification. A Student’s t-test was used to evaluate
the results.
Antibodies directed against a-dystroglycan (NCL-a-DG) diluted
in PBS 1:50, b- dystroglycan (NCL-b-DG) at 1:25 and dystrophin
(NCL-DYS1) at 1:10 were purchased from Novocastra (Newcastle
upon Tyne, UK). TGF-b1 was purchased from Santa Cruz, and
phospho-NFkB was purchased from Cell Signaling; both were
diluted 1:50 in PBS. The proteasome inhibitor bortezomib
(VelcadeH) was purchased from Janssen-Cilag Sa˜o Paulo (Butanta,
Sa˜o Paulo, Brazil).
Transmission Electron Microscopy (TEM)
Small pieces of muscle were fixed in Karnovsky modified
solution (2.5% glutaraldehyde and 2% paraformaldehyde in
0.1 M phosphate buffer). Fixed muscle samples were post-fixed
in 1% OsO4 and embedded in Epon-Araldite. Semi-thin (1 mm)
sections were stained with toluidine blue for detection of the region
of choice, and thin sections were stained on the grid with uranyl
acetate and lead citrate and examined in a Phillips 268D
transmission electron microscope at 60 or 80 kV.
Western blot analysis
Skeletal muscle tissues were harvested, minced with scissors,
homogenized in a Polytron tissue grinder for 30 s at medium
speed, and solubilized in buffer containing 10 mM Tris-HCl
(pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and
60 mM octyl glucoside for 45 min at 4uC. Samples were
centrifuged at 13,0006 g for 10 min at 4uC to remove insoluble
debris. The protein concentration was determined using a BCA kit
(Pierce). Soluble proteins were resolved by SDS-PAGE (10%
acrylamide) and transferred to nitrocellulose membranes. Blots
were blocked for 1 hour in TBST (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.2% Tween 20) containing 5% BSA. The
membranes were incubated overnight with the appropriate
primary antibody diluted in TBST/1% BSA. After three washes
with TBST, the blots were incubated for 30 minutes with
horseradish peroxidase (HRP)-conjugated secondary antibodies
diluted in TBST/1% BSA. Antibody-bound proteins were
detected using an ECL detection kit (Pierce). The blots were then
analyzed using ImageJ software [37]. See figures S1 and S2, for
methodological comprehension.
Clinical pathology and clinical signs
Blood from each dog was collected once a week for standard
serum biochemistry measurements and hematological examina-
tion during bortezomib administration. These samples were
processed by the Clinical Laboratory of the Department of Small
Animals, University of Sa˜o Paulo. The progression of muscular
dystrophy was monitored by clinical examinations performed once
per week for eleven weeks, beginning one week before the
administration of bortezomib and ending one week after the last
dose. The clinical examination included body condition, posture
and gait [32], [38], [39], hydration status, body weight, peripheral
lymph nodes, cardiac and respiratory auscultation, palpation and
abdominal inspection. The trunk and limbs were palpated and
inspected. Muscle mass and tone were evaluated [3], [40]. We also
considered the phenotypic variability associated with different
measurement tools, such as physical features, the passive range of
motion and the circumference of the limbs and thorax [39], while
evaluating the clinical symptoms.
Proteasome activity measurement in blood lysates
The chymotryptic activity of proteasomes was assessed using a
fluorogenic substrate assay [35], [41]. Venous blood (3 mL) was
collected from untreated and bortezomib-treated dystrophic dogs
in heparin-containing tubes 1, 4, and 24 hours post-treatment
during the first week of each cycle and stored at 220uC until
processing. The samples were placed at ambient temperature and
resuspended in PBS (1:1). The tubes were centrifuged at 2,0006 g
for 30 minutes at 4uC. The plasma was removed, and the buffy
coat samples were resuspended in 1 mL of PBS, aliquoted into
tubes and frozen at 220uC. Briefly, whole blood cells were lysed
with 5 mmol/L EDTA (pH 8.0) for 1 hour and centrifuged at
6006 g for 10 minutes at 4uC. The resultant whole blood lysate
samples were added to substrate buffer (20 mmol/L HEPES,
0.5 mmol/L EDTA, 0.05% sodium dodecyl sulfate, and
60 mmol/L chymotrypsin substrate-Suc-Leu-Leu-Val-Tyr–ami-
do-4-methylcoumarin (AMC) (Calbiochem-Novabiochem)). Ki-
netic measurements were performed at 37uC for one hour by
monitoring AMC release from the synthetic peptide substrate
LLVY-AMC. The samples from each animal were tested at least
three times for each time point, and the average was calculated.
The inhibition percentage was calculated using the expression 100
(1SpAI/SpAu), where SpAI is the chymotryptic activity of the
proteasome in the presence of the inhibitor bortezomib and SpAu
is the chymotryptic activity in the absence of bortezomib.
Statistical analysis
Non-parametric tests were used because the sample size was
relatively small. A Wilcoxon test was used to compare the
percentage of connective tissue deposition between the TD and
CD groups. Proteasome inhibition was analyzed in the samples
using a 95% confidence interval. Both of these tests were assessed
by the Core Team program (2008), and P values,0.05 were
considered statistically significant. For phospho-NF-kB, the
number of positive nuclei per field was quantified. The results
are expressed as the mean 6 SEM for the CD and TD groups
(n = 2). Statistical significance was set at P,0.05 using Student’s t-
test.
Results
Histology and ultrastructural analysis
At the first (T0) biopsy, which was made at three months of age
and before bortezomib therapy, the muscle fibers showed myofiber
hypertrophy, fiber necrosis and regeneration. Discrete endomysial
Bortezomib Therapy in Canine Dystrophy
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fibrosis and myofiber atrophy were also observed. At this stage,
myofibers showed a basophilic cytoplasm and were designated
regenerative fibers.
At T1, at the end of the experiment, small fibers undergoing
phagocytosis were observed. The amount of these fibers was
increased compared to T0. The inflammatory process was
predominantly composed of macrophages. At this time, there
was a slight increase in endomysial and perimysial connective
tissue (endomysial fibrosis), and marked myofiber atrophy in all
sections was observed.
Skeletal muscle collected at T1 from CD showed an abnormal-
affected fiber-forming group of lesions characterized by inflam-
matory cell infiltration. These dogs presented myopathic changes
such as variability in fiber diameter, lymphocytic invasion and
increased deposition of connective tissue in the perimysium.
Meanwhile, the two TD (K1 and B7) showed a more uniform fiber
diameter and less lymphocytic invasion, suggesting an attenuated
inflammatory process and reduced signs of muscular dystrophy.
The same phenomena were not observed in CD (K4 and K6)
(Figures 1A–D), showing that systemic administration of bortezo-
mib seems to ameliorate muscle fiber degeneration, thereby
improving skeletal muscle pathology.
At T0, there was no difference between the collagen deposition
areas of TD and CD. However, at T1, TD showed 7.39% collagen
per mm2 and CD showed 13.42% collagen per mm2. In 30 random
thin-section images from each dog, there was a significant
difference between T0 and T1 (p,0.05) for CD, and a significant
difference between TD and CD at T1 (p = 0.0028). These data
suggest a greater degree of muscle fibrosis in CD muscle
(Figure 1E).
Confirming the findings from muscle histology, transmission
electron microscopy (TEM) analysis showed infiltration of
inflammatory cells, degenerated fibers, and the presence of
activated fibroblasts in the perimysium. The TEM data indicate
that connective tissue synthesis and fibrosis were present in all
studied dogs; however, the CD showed greater deposition of
collagen fibers in the endomysium and perimysium (Figures 2A–
D).
Ultrastructural analysis also demonstrated abnormal mitochon-
dria in the cytoplasm and close to the sarcoplasmic membrane in
all studied dogs. These mitochondria had a higher electron density
and were smaller than those observed in healthy dogs. The
morphology of the mitochondria was preserved, and the cristae
had a similar electron density to those present at the myofibers of
healthy dogs. Abnormal mitochondria were observed in almost all
healthy-appearing muscle from the GRMD dogs (Figures 2E and
F).
Fully abnormal fibers showed a complete loss of myofibrillar
structure and a finely granular cytoplasm associated with loss of
membrane integrity. Satellite cells associated with degenerating
fibers appeared to be activated, with nuclear enlargement and
clearing, reduced heterochromatin, and a greater number of
cytoplasmic organelles. Numerous macrophages and fibroblasts
with prominent rough endoplasmic reticulum were observed in the
endomysium (Figures 2G and H).
Immunohistochemistry (IHC)
Previous studies have shown that treatment with proteasome
inhibitors can block protein degradation and rescue dystrophin
and dystrophin-associated proteins in vivo in the muscle fibers of
mdx mice and in vitro in human muscle [19], [27], [30]. Local
administration of bortezomib and MLN273 were effective at
rescuing the expression and plasma membrane localization of
dystrophin and dystrophin-associated proteins a-dystroglycan, b-
dystroglycan, and a-sarcoglycan [19].
To confirm the results obtained by histology and ultrastructural
analysis of connective tissue deposition and fibrosis, we analyzed
the expression of TGF-b by immunohistochemistry. The untreat-
ed dogs showed higher TGF-b expression in the slides analyzed,
indicating higher levels of connective tissue deposition and fibrosis
in these animals (Figures 3A–D).
Immunohistochemical staining for the carboxy-terminal portion
of dystrophin was positive in the control samples from healthy
dogs and negative in muscle sections of GRMD dogs from both
groups. The treated dogs did not show dystrophin staining in the
cytoplasmic membrane (Figures 3E–H), suggesting that bortezo-
mib treatment is not an effective way to rescue dystrophin
production in the muscle membrane.
Among the other proteins in the dystrophin-glycoprotein
complex, the expression levels of a-dystroglycan and b-dystrogly-
can were increased in GRMD dogs treated with bortezomib
compared with the untreated dogs (Figures 4 and 5). This result
indicates that bortezomib rescues the expression of these proteins
and ameliorates the histopathological phenotype. Using ImageJ
software and analyzing the expression of the protein of interest
divided by the expression of the internal control, we observed a
fourfold increase in the expression of a-dystroglycan (TD-B7) and
a twofold increase in the expression of b-dystroglycan for TD-K1
(Figure 4D and Figure 5D). However the studies performed
suggest a rescue of important dystrophic proteins that would need
to be confirmed with future experiments with additional animals
and appropriate quantitative and statistical analysis. Many
researchers have reported that sustained activation of the nuclear
factor-kappa B (NFkB) pathway is involved in inflammatory
myopathies and DMD. Thus, we next tested whether administra-
tion of bortezomib reduced NFkB levels. Based on 10 random
micrographs per dog of muscle sections stained for phospho-NFkB
(the active phosphorylated form of NFkB), there was a lower level
of staining in the treated dogs compared to untreated dogs. This
result indicates blockage of IkK and the consequent inflammatory
process (Figure 6). Our immunohistochemical analysis revealed
increased staining for phospho-NFkB in atrophic and regenerative
fibers, and quantitative studies of positive nuclear activity showed
significantly lower levels in treated dogs than untreated dogs
(p,0.05) (Figure 6).
Clinical pathology and clinical signs
Serum creatine kinase (CK) levels were dramatically elevated in
both groups of GRMD dogs compared to healthy dogs at all time
points, as were the levels of serum alanine aminotransferase (ALT)
and aspartate aminotransferase (AST). The level of these enzymes
peaked at the fourth week when the dogs were four months old,
indicating muscle necrosis featuring dystrophic myopathy. We also
observed a high serum electrolyte level (phosphorus, potassium)
and a significant hematological finding of thrombocytosis. Urea
and creatinine levels were within the laboratory reference ranges
(Table 1).
All of the GRMD dogs showed progressive clinical signs with
muscle atrophy involving all four limbs, exercise intolerance, and
abnormal gait. Dysphagia, regurgitation, and dyspnea may occur
as a result of hypertrophy of the lingual, pharyngeal, and
esophageal musculature. We observed different phenotypes in
the GRMD dogs, even though they were the same age and four of
them were littermates. Table 2 indicates the main clinical signs
observed in all dogs, regardless of whether they were treated or
untreated.
Bortezomib Therapy in Canine Dystrophy
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One treated dog (B7) presented bilateral acute conjunctivitis in
the last treatment cycle (receiving 1.6 mg/m2 of bortezomib). The
sclera of the dog was slightly reddish, with the periocular area
crusty and lacerated. This dog was sent to the ophthalmology
clinic for Small Animals at the University of Sa˜o Paulo (FMVZ-
USP) for additional exams. The dog was shown to be suffering
from an acute allergic reaction, suggesting that the drug treatment
could induce lesions. In another treated dog (K1), the progressive
clinical signs of muscular dystrophy induced contractures and
deformations in caudal limbs. These signs began at four months of
age and continued until the dog became unable to walk with the
caudal limbs. The untreated dog (K4) presented progressive
clinical signs of muscular dystrophy beginning at 8 months and
causing death at 10 months.
Proteasome activities in blood lysates
Because chymotrypsin-like activity is the principal target of
proteasome inhibitors, this activity was evaluated for each of the
samples as a measure of proteasome activity. Effect of the drug is
dose-dependent, with a positive change in fiber integrity only
occurring at the maximum dosage of proteasomal inhibitor [27].
Twelve tests were conducted, with a minimum of three tests and
a maximum of five tests from each animal per time point. Control
samples were also used in all experiments. As expected, the
negative control group of healthy animals had low chymotrypsin-
like activity, while muscle extract from cachectic rats with high
chymotrypsin-like activity was used as a positive control.
During the first cycle, with the dose set at 1.3 mg/m2, the
treated GRMD dogs B7 showed and K1 showed 72.6% and
66.1% proteasome inhibition, respectively, during the first hour of
evaluation. In the second cycle, a higher rate of inhibition was
shown compared with the first cycle, with B7 demonstrating
80.6% proteasome inhibition. K1 showed a lower value of
proteasome inhibition at approximately 47.6%.
Maximal inhibition of the proteasome levels in blood was
observed 1 hour after bortezomib administration in the last cycle
when the dose was 1.6 mg/m2, and a satisfactory level of
inhibition was maintained for 4 hours. Proteasome inhibition
Figure 1. Histological analysis of H&E-stained skeletal muscle fibers after treatment with bortezomib and muscle collagen
morphometry. A and B: CD showed a greater deposition of connective tissue in the endomysium and perimysium (c), and the inflammatory cells
formed groups or massive lesions (*) with a poor histopathological appearance. C and D: TD showed lower deposition of connective tissue in
endomysium and perimysium (c) and a lower presence of inflammatory cells (*); Original magnification: 106; bar: 200 mm. E: Mean and SD of muscle
collagen morphometry of slides stained with picrosirius red followed by quantitative analysis. Muscle from healthy dogs and TD and CD before (T0)
and after (T1) treatment with bortezomib. The p-value was ,0.0001 for comparing the collagen at T0 and T1 for CD. At T1 there was a statistically
significant difference between the TD and CD, with higher collagen levels in CD (p= 0.0028).
doi:10.1371/journal.pone.0061367.g001
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increased to 90% for dogs B7 and K1. After 24 hours, the levels of
inhibition were similar to those of the CD (Figure 7). These data
show that bortezomib inhibits 20S proteasome activity in the
plasma of treated GRMD dogs in a dose-dependent manner, with
maximal inhibition 1 hour after drug administration for each cycle
studied.
In the third cycle, the last dose resulted in up to 90% inhibition
of 20S proteasome activity, and dog B7 showed acute conjunc-
tivitis and periocular lacerative lesions, side effects also found in 3–
4% of human patients treated with bortezomib (Millennium
Pharmaceuticals, unpublished data).
Discussion
Recent studies have demonstrated that inhibitors of the
proteasome pathway can effectively block the degradation of
dystrophin and dystrophin-associated proteins and ameliorate the
myopathic changes characteristic of dystrophin-deficient skeletal
muscle [19], [27], [30] and a-sarcoglycan-deficient muscle [42].
We studied muscle fiber morphology at time 0 (before
treatment) for both groups (TD and CD). The predominant
histopathological signs were myofiber hypertrophy, fiber necrosis
and regeneration, discrete endomysial fibrosis and marked
myofiber atrophy [6], [43].
At the end of the treatment, treated dogs showed a more
uniform fiber diameter and less lymphocytic invasion, suggesting
that the inflammatory process was attenuated and that there was
reduced connective tissue deposition in the endomysium and
perimysium of muscle fibers. These results are relevant because the
accumulation of endomysial and perimysial connective tissue in
unused and dystrophin-deficient muscles may contribute to the
impairment of intra-muscular blood circulation. The scarcity of
capillaries may, in turn, lead to increased amounts of connective
Figure 2. Ultrastructural analysis of connective tissue in
muscles from GRMD dogs. A: Muscle from a healthy dog. There
was a narrow endomysium space and a lower deposition of connective
tissue (R). B: An untreated GRMD dog (CD). The endomysium of this
dog exhibits a higher deposition of connective tissue and hypercon-
tracted fibers (HF). C and D: Treated GRMD dogs (TD) showed a lower
deposition of connective tissue and endomysium, and few fibers were
hypercontracted (HF). Original magnification: 3,5006. E: In muscles
from healthy dogs, the mitochondria were preserved and had the same
electron density as the fibers, and the mitochondrial cristae were visible.
F: GRMD dogs demonstrated abnormal mitochondria, had a higher
electron density, and were smaller, and the cristae were not visible. G
and H: Abnormal fiber (NF) with macrophage invasion (M), complete
loss of membrane integrity and myofibrillar structure showing a finely
granular cytoplasm. Activated fibroblasts (F) with a prominent rough
endoplasmic reticulum (R) were present in the endomysium. Original
magnification: A and B, 8,9006; C, 3,5006; D, 5,6006.
doi:10.1371/journal.pone.0061367.g002
Figure 3. Immunohistochemistry of TGF-b and dystrophin in
skeletal muscle. A and E. Muscle from healthy dogs. TGF-b is
detected around the vessels in muscles (A), a-dystroglycan (E) and
dystrophin (I) patterns in the sarcoplasmic membrane. B: Muscle from
CD at T1 shows greater TGF-b expression in the endomysium of the
fibers and more deposition of connective tissue at T1. C and D: TD
after treatment with bortezomib (T1) showed lower deposition of
connective tissue and lower expression of TGF-b in the endomysium of
the fibers. Original magnification: 406; bar: 50 mm. F, G and H: Neither
untreated (CD) (J) nor treated GRMD dogs (TD) (K and L) showed
expression of dystrophin in the sarcoplasmic membrane, indicating that
bortezomib did not rescue this protein during the treatment. Original
magnification: 206; bar: 100 mm.
doi:10.1371/journal.pone.0061367.g003
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tissue, initiating a vicious cycle [33]. It has also been suggested that
this scar tissue may itself assume a pathogenic role and contribute
to disease progression by interfering with effective muscle
regeneration and reinnervation [44].
One significant difference between the biopsies at T0 and T1
was the presence of inflammatory cells in the endomysium of the
fibers in the T1 samples. Same observation was found at literature
and suggested that mast cell degranulation plays a role in inducing
Figure 4. Immunohistochemistry and western blot for a-dystroglycan. A: Muscle from a healthy dog shows the a-dystroglycan pattern in
sarcoplasmic membranes. B: Untreated GRMD dog (CD). C and D: Western blot and immunohistochemical analysis from a TD showing higher
expression of a-dystroglycan in muscle fibers than CD after treatment with bortezomib. Using ImageJ software and measuring the blot band
intensity, we suggest that TD-B7 had a 4-fold increase in the expression of a-dystroglycan. Original magnification: 406; bar: 50 mm.
doi:10.1371/journal.pone.0061367.g004
Figure 5. Immunohistochemistry and western blot for b-dystroglycan. A: Muscle from a healthy dog shows the b-dystroglycan pattern in
sarcoplasmic membranes. B: Untreated GRMD dog. C and D: Western blot and immunohistochemical analysis from a TD show higher expression of
b-dystroglycan in muscle fibers than CD after treatment with bortezomib. Using ImageJ software and measuring the blot band intensity, we found
that TD-K1 had a 2-fold increase in the expression of b-dystroglycan. Original magnification: 406; bar: 50 mm.
doi:10.1371/journal.pone.0061367.g005
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myofiber death [45]. Mutations in dystrophin result in membrane
damage, allowing massive infiltration of immune cells, chronic
inflammation, necrosis, severe muscle degeneration [46] and an
invasion of inflammatory cells [47] such as macrophages and T-
lymphocytes [48].
Ultrastructural studies of Duchenne dystrophy indicate that
hypercontraction of fibers is an early change, followed by
myofibrillar lysis and total fiber necrosis, with macrophage
invasion as a late event [49]. Although the integrity of the plasma
membrane and mitochondria appeared to be preserved during the
early stages of degeneration [50] and noted no structural
abnormalities in adjacent normal-appearing fibers, we observed
hypercontracted fibers in both groups. The most important sign of
degeneration was highly electron-dense mitochondria, suggesting
Figure 6. Immunohistochemistry of phospho-NFkB in skeletal muscle. A and C: Muscle from a CD shows higher expression of the (active)
phospho-NFkB in the nuclei of muscle fibers. B and D: GRMD dogs (TD), after treatment with bortezomib, showed a lower expression of phospho-
NFkB in the nuclei of fibers, indicating proteasome inhibition and preservation of inactive NFkB in the cytoplasm. Original magnification: A and B,
106; bar, 200 mm; C and D, 206; bar, 100 mm. E: The phospho-NFkB positive nuclei were counted in 10 random fields, with images captured at 406.
Student’s t-test was used to evaluate these results (* p,0.05). The CD showed more phospho-NFkB-positive nuclei, indicating more activation of
proteasomal activity inducing pro-apoptotic factors and inflammatory molecules.
doi:10.1371/journal.pone.0061367.g006
Table 1. Serum and hematological parameters in GRMD dogs.
Dogs Untreated dogs (CD) Treated dogs (TD) Refer. values
Parameter K3 K4 K6 K1 B7
CK (UI/L) 14436 15168 8512.6 15906 8779.3 68–200
ALT (UI/L) 503.1 420.3 304.3 405.5 311.2 10–130
AST (UI/L) 348.2 417.1 190.8 306.9 244.6 23–66
Phosphorus (mg/dL) 7.7 9 8.7 8.7 8.6 2.5–6.2
Potassium (mEq/L) 5.5 5.4 5.9 5.2 5.6 3.6–5.8
Platelets (mL) 521667 512667 717556 591000 561444 2–5 105
Mean values for altered serum and hematological parameters from GRMD dogs during the nine weeks of the study. The times represent the bortezomib treatment
period in the treated dogs (K1 and B7). The parameter with the greatest change was serum CK concentration, with a high magnitude range of 40 to 70 times the
reference value from Kaneko et al. (1997). CK: creatine kinase
doi:10.1371/journal.pone.0061367.t001
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degeneration. We also noted macrophages inside the fibers,
degenerated products, activated fibroblasts and connective tissue
deposition in the endomysium and perimysium of the fibers[50].
Previous reports have shown that the effect of proteasomal
inhibitors (MG-132, bortezomib and MLN-273) is dose-dependent
and that positive changes in fiber integrity only occur at the
maximum dosage delivered [19], [26]. In light of these reports, we
chose to measure the percentage of proteasome inhibition in blood
cells for each cycle of bortezomib treatment. The recent literature
has shown a diversity of expression and activities for the ubiquitin-
proteasome and calpain systems in GRMD muscle, leading to
unexpected consequences such as heart-related cardiomyocyte
lesions in response to pharmacological inhibition [51].
Previous in vitro studies have shown that maximal proteasome
inhibition occurs 1 hour after administration of bortezomib
[41,52]. Reports [35] demonstrated maximal inhibition of the
20S proteasome, one hour after drug administration. The 20S
proteasome activity began to recover after 4 hours, and 50%
recovery had occurred at 24 hours. These studies agree with our
present results.
In the final cycle, we observed up to 90% inhibition of
proteasome activity in drug-treated dogs, but we observed an
adverse effect, namely acute conjunctivitis, as well. The dose-
limiting toxicity in animal species occurs at approximately 90%
20S proteasome inhibition. Although the specific major dose-
limiting toxicity (DLT) varied from schedule to schedule,
neuropathy, diarrhea, and fatigue are the predominant toxicities
Table 2. Clinical signs in GRMD dogs.
Dogs age
4 months 5 months 6 months
- Rigidity of pelvic and thoracic limbs
- Gait abnormalities
-Clinical signs of 4 months plus:
- Quadriceps rigidity
- Hard to open mouth
- Muscle atrophy
Clinical signs of 5 months plus:
-Excess salivation and dysphagia
-Increase in the resting respiratory rate and excessive
abdominal component to breathing
- Muscle contractures
The main clinical signs observed in GRMD dogs during treatment with bortezomib (three, four and five months of age). There were different phenotypes, but the main
clinical signs related to muscular dystrophy progression were common to all of the dogs in the study. For physiological studies of GRMD, please see the reference [63]
showing an in situ protocol to measure the force generated by a single muscle in dogs.
doi:10.1371/journal.pone.0061367.t002
Figure 7. Chymotrypsin-like activity in blood lysate. Representative scheme for the in vitro assessment of 20S proteasome chymotrypsin-like
activity by monitoring the release of the fluorophore AMC from the synthetic peptide substrate LLVY-AMC. We analyzed the chymotryptic-like activity
in the blood lysate of TD, CD, healthy dogs (negative control) and the cachectic muscles taken from mice (positive control). Significant inhibition of
20S proteasome activity was observed within 1 hour of dosing in all cycles of treatment, after which the inhibition decayed. A: B7 and K1 showed
higher proteasome inhibition at the first hour after treatment. B: B7 showed higher inhibition at the first hour after treatment. C: B7 and K1 showed
higher proteasome inhibition at the first hour (** p,0.05) and four hours after treatment.
doi:10.1371/journal.pone.0061367.g007
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observed in treated humans [53]. Chronic proteasome inhibition is
associated with increased coronary artery oxidative stress and early
atherosclerosis [54]; because cardiomyopathy is a consequence of
DMD, the chronic use of bortezomib should be associated with
other therapies and used with caution in these patients. We
observed no significant differences between the biochemical
profiles of treated and untreated dogs. The most important
findings were increases in the CK, AST and ALT levels in all
GRMD dogs over time. The CK serum concentration is relevant
for the diagnosis of muscle diseases, and muscular dystrophy in
dogs is associated with increased CK [2], [3], [55]. AST and ALT
are also involved in muscular dystrophy, and similarly to CK, their
increased levels suggest muscle necrosis and myopathy [42], [56].
Our results indicated progression of muscle disease in both groups
of dogs, even though we observed rescue of the DGC proteins and
amelioration of the muscle fibers. Our study demonstrates for the
first time not only the rescue of DGC proteins but also the clinical
signs associated with the use of proteasome inhibitor in dogs with
muscular dystrophy. To evaluate the possible rescue of dystrophin
and dystrophin-associated proteins, we performed immunohisto-
chemical analyses of dystrophin and a- and b-dystroglycan. We
were unable to demonstrate dystrophin rescue in muscle
membranes. However, drug-treated dogs showed increased a-
and b-dystroglycan expression, indicating an improvement in the
disease histopathology phenotype.
Previous reports have shown increased NFkB in muscle atrophy
[57] and muscular dystrophy [17],[18], [58], [59], and it has been
reported that proteasomal inhibitors are able to block the
activation of NFkB in the muscle fibers of mdx mice [15].
By blocking proteasomal activity, bortezomib prevents the
activation of NFkB, thus reducing the accumulation of anti-
apoptotic factors and inflammatory molecules. We performed an
immunohistochemical analysis for phospho-NFkB (the active form
of NFkB) and observed increased levels of phospho-NFkB in
untreated dogs. This result confirmed the morphology we
observed, with more inflammatory and abnormal fibers in
untreated dogs. Intense immunostaining for phospho-NFkB was
observed in atrophic, necrotic and regenerating fibers and
primarily appeared near areas of mononuclear cell infiltrates
[26]. Similar results were found using the proteasome inhibitors
bortezomib and MLN273 [19].
The activation of NFkB and the acute activation of TGF-b1 in
human dystrophin-deficient muscle cause metabolic pathway
failure later in the disease and appear to be associated with
symptoms and muscle wasting in DMD [21]. Proteasome
inhibitors may ameliorate the dystrophic process by preventing
the proteolysis of the dystrophin complex, thereby preserving the
stability of the muscle fiber and modulating the fibrogenic (TGF-
b1) and inflammatory responses (NFkB) [60]. TGF-b1 release
from muscle degeneration may trigger the activation of extracel-
lular matrix proteins, and this activation could lead to connective
tissue proliferation [21], [61]. Untreated dogs had higher levels of
TGF-b1 expression as determined by immunohistochemical
analysis, microscopy and ultrastructural analysis. This result
suggests that treatment with bortezomib may decrease connective
tissue formation and fibrosis in GRMD dogs.
The expression of TGF-b1 in the early stages of DMD may be
critical for initiating muscle fibrosis, and antifibrosis treatment
might slow the progression of the disease, increasing the utility of
gene therapy [21], [22]. We started bortezomib treatments before
moderate-to severe clinical signs appeared in these dogs so that the
possible rescue of DGC proteins could be evaluated before the
fibrotic process had fully developed. Thus, we used dogs less than
5 months of age; however, the effects of this drug in older dogs,
when the disease is well established, are not clear. It is now
suggested in humans that a combination therapy using different
agents leads to a better quality of life in these patients and
decreases the complications of their degenerative and progressive
illness [62].
Conclusions
In conclusion, bortezomib can be safely administered as an
intravenous bolus without premedication, and it is very well
tolerated in dogs when administered according to the dose and
schedule recommended. Inhibition of the proteasome was dosage-
dependent, with maximal proteasome inhibition in the plasma of
treated dogs occurring at the maximum dosage during the last
cycle of treatment. Bortezomib was able to reduce the infiltration
of inflammatory cells into the muscle fibers of TD, and the dogs
had a lower deposition of connective tissue as a result of necrosis
and muscle atrophy than CD. This finding suggests that a
proteasomal inhibitor can improve the histopathological appear-
ance of dystrophin-deficient skeletal muscle. While dystrophin was
not rescued, dystrophin-associated proteins belonging to the DGC
complex (b-dystroglycan and a-dystroglycan) were rescued in
treated dogs. Our findings suggest that bortezomib can block the
activation of phospho-NFkB, which may be important in the
pathogenesis of DMD and may represent one line of research in
Duchenne therapy. No single treatment will be sufficient to reverse
the signs of disease, and therapeutic combinations can provide
opportunities to control and understand the disease condition.
Unfortunately, other parameters, such as clinical signs and the
serum biochemistry measurements of CK, AST and ALT, were
altered in both groups studied, indicating that the disease
progressed despite treatment.
Supporting Information
Figure S1 Alpha-dystroglycan and GAPDH western blot
analysis. A: nitrocellulose membranes were cut in two parts and
exposed each one to alpha-DG or GAPDH. B: Alpha-dystrogly-
can analysis (clone IIH6, Santa Cruz Biotechnology) 1:500 diluted
in TBS. We observed 97 kDa band between 125 and 88 kDa in
B7 (TD group) indicating rescue of alpha-dystroglycan after
treatment with bortezomib. C: GAPDH analysis (clone 1D4 Gene
Tex) 1:1000 diluted in TBS, the 37 kDa band is observed between
36 and 72 kDa.
(TIF)
Figure S2 Beta-dystroglycan and beta-actin western blot
analysis. A: nitrocellulose membranes were exposed to anti beta-
DG and the antibody was then stripped, and the same membrane
was revealed with anti beta-actin. B: Beta-dystroglycan analysis
(clone 43DAG1/8D5, Novocastra) 1:500 diluted in TBS. We
observed 45 kDa band between 50 and 34 kDa, indicating rescue
of beta-dystroglycan protein in TD group after treatment with
bortezomib C: Beta-actin analysis (clone 8H10D10 Cell Signaling)
1:10000 diluted in TBS, the 42 kDa band is observed between 50
and 34 kDa.
(TIF)
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